High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells

Chemical Biology and Drug Design

Volumn 82, Issue 2, 2013, Pages 131-139

  Henrich, Curtis J ^a,b   Budhu, Anuradha ^c   Yu, Zhipeng ^c   Evans, Jason R ^a,d   Goncharova, Ekaterina I ^a,d   Ransom, Tanya T ^a   Wang, Xin W ^c   Mcmahon, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Data Management Services Inc   (United States)

Author keywords

Epithelial cell adhesion molecule; Hepatocellular carcinoma; High throughput screening; Wnt catenin

Indexed keywords

BETA CATENIN; EPITHELIAL CELL ADHESION MOLECULE;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DEATH; CELL DENSITY; CELL GROWTH; CELL POPULATION; CELL SURVIVAL; DNA FRAGMENTATION; FLOW CYTOMETRY; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; LIVER CELL CARCINOMA; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY;

EID: 84880753409     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12146     Document Type: Article

References (22)

1. Whittaker S., Marais R., Zhu A.X. (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene;29:4989-5005.
2. Barker N., Clevers H. (2006) Mining the wnt pathway for cancer therapeutics. Nat Rev Drug Discov;5:997-1014.
3. Trosset J.Y., Calvit C., Knapp S., Fasolini M., Veronesi M., Mantegani S., Gianellini L.M., Catana C., Sunstrom M., Stouten P.F., Moll J.K. (2006) Inhibition of protein-protein interactins: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins;64:60-67.
4. Kawamoto S.A., Thompson A.D., Coleska A., Nikolovska-Coleska Z., Yi H., Wang S. (2009) Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. Biochemistry;48:9534-9541.
5. Ewan K., Pajak B., Stubbs M., Todo H., Barbeau O., Quevedo C., Botfield H. et al. (2010) A useful approach to identify novel small-molecule inhibitors of wnt-dependent transcription. Cancer Res;70:5963-5973.
6. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., Shivdasani R.A. (2004) Small-molecule antagonists of the oncogenic Tcr/beta-catenin protein complex. Cancer Cell;5:91-102.
7. Herlyn M., Steplewski Z., Herlyn D., Koprowski H. (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA;76:1438-1442.
8. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.-Y., Jia H. et al. (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology;136:1012-1024.
9. Munz M., Baeuerle P.A., Gires O. (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res;69:5627-5629.
10. Terris B., Carvard C., Perret C. (2010) EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol;52:280-281.
11. Yamashita T., Budhu A., Forgues M., Wang X.W. (2007) Activation of hepatic stem cell marker EpCAM by wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res;67:10831-10839.
12. Oishi N., Wang X.W. (2011) Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci;7:517-535.
13. van der Gun B.T.F., Melchers L.J., Ruiters M.H.J., de Leij L.F.M.H., McLaughlin P.M.J., Rots M.G. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis;31:1913-1921.
14. Patriarca C., Macchi R.M., Marschner A.K., Mellstedt H. (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev;38:68-75.
15. + cell population in hepatocellular carcinoma cell lines. Cancer Sci;101:2145-2155.
16. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res;48:4827-4833.
17. Nelson E.A., Walker S.R., Weisberg E., Bar-Natan M., Barrett R., Gashin L.B., Terrell S., Klitgarrd J.L., Santo L., Addorio M.R., Ebert B.L., Griffin J.D., Frank D.A. (2011) The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood;117:3421-3429.
18. Sahm C., Schonfeld K., Wels W.S. (2012) Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother;61:1451-1461.
19. Muraoka-Cook R.S., Sandahl M.A., Strunk K.E., Miraglia L.C., Husted C., Hunter D.M., Elenius K., Chodosh L.A., Earp H.S. III (2009) ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol;29:4935-4948.
20. Wang R., Xie H., Huang Z., Ma J., Fang X., Ding Y., Sun Z. (2011) T cell factor 1 regulates thymocyte survival via a RORγt-dependent pathway. J Immunol;187:5964-5973.
21. Tong A.W., Su D., Mues G., Tillery G.W., Goldstein R., Klintmalm G., Stone M.J. (1996) Chemosensitization of human hepatocellular carcinoma cells with cyclosporine A in post-liver transplant patient plasma. Clin Cancer Res;2:531-539.
22. Maetzel D., Denzel S., Mack B., Canis M., Went P., Benk M., Kieu C., Papior P., Baeuerle P.A., Munz M., Gires O. (2009) Nuclear signaling by tumour-associated antigen EpCAM. Nat Cell Biol;11:162-171.